Appl. No. 10/788,666
Preliminary dated August 16, 2004
Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1.   (Original) A method of preventing or treating a disease characterized by amyloid deposit in a patient, comprising administering an effective dosage of an antibody that specifically binds to the amyloid deposit or a component thereof to the patient.

2-37. (Canceled)

38.   (Original) A method of preventing or treating Alzheimer's disease, comprising administering an effective dosage of a polypeptide comprising an active fragment of Aβ that induces an immune response to Aβ in the patient.

38-53. (Canceled)

54.   (Original) A method of screening an antibody to Aβ or an active fragment of Aβ for use in treatment of Alzheimer's disease, comprising:

administering an antibody that specifically binds to Aβ or a fragment of AB to a transgenic animal disposed to develop characteristics of Alzheimer's disease;

detecting a reduction in the extent or rate of development of the characteristics relative to a control transgenic animal.

55.   (Original) The method of claim 54, further comprising screening a population of antibodies to identify an antibody that binds to an epitope within amino acids 1-28 of Aβ.

56.   (Original) A method for effecting rapid improvement of cognition in a subject having a condition or disease related to Aβ, comprising administering to the subject an effective amount of an anti-Aβ antibody.

57. (Original) The method of Claim 56, wherein the subject is human.

58. (Currently Amended) The method of Claim 57, wherein the condition or disease is Alzheimer's disease, Down's syndrome, ~~cerebral amyloid angiopathy,~~ or mild cognitive impairment.

59. (Original) The method of Claim 58, wherein the disease is Alzheimer's disease.

60. (Currently Amended) The method of Claim 58, wherein the disease or condition is Down's syndrome.

61. (Canceled)

62. (Original) The method of Claim 58, wherein the disease or condition is mild cognitive impairment.

63. (Currently Amended) The method of any one of <u>claims 56-60 and 62</u>~~Claims 56-62~~, wherein the antibody has greater affinity for soluble Aβ than 10^{-9} M.

64. (Currently Amended) The method of any one of <u>claims 56-60 and 62</u>~~Claims 56-62~~, wherein the antibody has greater affinity for soluble Aβ than humanized antibody 266.

65. (Currently Amended) The method of any one of <u>claims 56-60 and 62</u>~~Claims 56-62~~, wherein the antibody has greater affinity for soluble Aβ than 10^{-10} M.

66. (Canceled)

67. (Currently Amended) The method of any one of <u>claims 56-60 and 62</u>~~Claims 56-66~~, wherein the antibody is a humanized or human antibody.

Appl. No. 10/788,666
Preliminary dated August 16, 2004
Page 4

68.   (Original) The method of Claim 67, wherein the antibody is a humanized 266 antibody, or an analog thereof.

69.   (Currently Amended) The method of any one of ~~claims 56-60 and 62~~claims 56-68, wherein the anti-Aβ antibody recognizes the same epitope that antibody 266 recognizes or competes with antibody 266 for binding to soluble. Aβ.

70.   (Currently Amended) The method of claim 63~~any one of claims 56-69~~, wherein the affinity is measured with respect to either Aβ1-40 or Aβ1-42.

71.   (Currently Amended) The method of any one of ~~claims 56-60 and 62~~claims 56-70, additionally comprising measuring cognition in the subject before administering the antibody.

72.   (Original) The method of claim 71, additionally comprising measuring cognition in the subject after administering the antibody.

73.   (Canceled)

74.   (Currently Amended) The method of any one of ~~claims 56-60 and 62~~claims 56-73, additionally comprising measuring cognition in the subject after administrating the antibody.

75.   (Currently Amended) The use of an anti-Aβ antibody to prepare a medicament for any one of the methods of claims 56-60 and 62~~claims 56-74~~.

76.   (Currently Amended) A method for treating cognitive symptoms of a condition or disease associated~~associate~~ with Aβ in a subject, comprising administering to the subject an effective amount of an anti-Aβ antibody that has greater affinity for soluble Aβ than 10^{-9} M.

77.   (Currently Amended) A method for reducing disease progression in a subject having a condition or disease associated~~associate~~ with Aβ, comprising administering to

Appl. No. 10/788,666
Preliminary dated August 16, 2004
Page 5

the subject an effective amount of an anti-Aβ antibody that has greater affinity for soluble Aβ than 10^{-9} M.

78.   (Original) A method for treating cognitive symptoms of a condition or disease associated with Aβ in a subject, comprising administering to the subject an effective amount of an anti-Aβ antibody that has affinity (KD) for soluble Aβ1-40 or Aβ1-42 higher than 10^{-9} M.

79.   (Currently Amended) A method for reducing disease progression in a subject having a condition or disease associated~~associate~~ with Aβ, comprising administering to the subject an effective~~aneffective~~ amount of an anti-Aβ antibody that has affinity (KD) for soluble Aβ1-40 or Aβ1-42 higher than 10^{-9} M.

80.   (Original) A method for treating cognitive symptoms of a condition or disease associated Aβ in a subject, comprising administering to the subject an effective amount of an anti- Aβ antibody that has greater affinity for soluble Aβ than antibody 266 has.

81.   (Currently Amended) A method for reducing disease progression in a subject having a condition or disease associated~~associate~~ with Aβ, comprising administering to the subject an effective amount of an anti- Aβ antibody that has great affinity for soluble Aβ than antibody 266 has.

82.   (Original) The method any one of claims 76-81, wherein the anti- Aβ antibody has greater affinity for soluble Aβ than 10^{-10} M.

83-84. (Canceled)

85.   (Currently Amended) The method of any one of claims 76-82~~claims 76-84~~, wherein the affinity of the anti- Aβ antibody is measure with respect to soluble Aβ1-40 or Aβ1-42.

86.   (Currently Amended) The method of any one of claims 76-82claims 76-85, wherein the subject is human and the anti- Aβ antibody is human or humanized antibody.

87.   (Currently Amended) The method of any one of claims 76-82claims 76-86, wherein the anti- Aβ antibody recognizes the same epitope that antibody 266 recognizes or competes with antibody 266 for binding to soluble is a human Aβ.

88.   (Currently Amended) The method of any one of claims 76-82claims 76-87, wherein the condition or disease is Alzheimer's disease.

89.   (Currently Amended) The method of any one of claims 76-82claims 76-87, wherein the condition or disease is Down's syndrome.

90.   (Canceled)

91.   (Currently Amended) The method of any one of claims 76-82claims 76-87, wherein the condition or disease is vascular dementia.

92.   (Currently Amended) The method of any one of claims 76-82claims 76-87, wherein the condition or disease is mild cognitive impairment.

93.   (Currently Amended) The use of an anti-Aβ antibody having affinity (KD) for soluble Aβ1-40 or Aβ1-42 higher than 10^{-9} M to prepare a medicament for treating cognitive symptoms of a condition or disease associatedassociate with Aβ.

94.   (Currently Amended) The use of an anti-Aβ antibody having affinity (KD) for soluble Aβ1-40 or Aβ1-42 higher than 10^{-9} M to prepare a medicament for reducing disease progression in a subject having a condition or disease associatedassociate with Aβ.

95.   (Original) The use of an anti-Aβ antibody having affinity for soluble Aβ than antibody 266 has to prepare a medicament for treating cognitive symptoms in a subject having a condition or disease associated with Aβ.

Appl. No. 10/788,666
Preliminary dated August 16, 2004
Page 7

96.　(Currently Amended)　The use of an anti-Aβ antibody having greater affinity for soluble Aβ than antibody 266 has to prepare a medicament for reducing disease progression in a subject having a condition or disease associatedassociate with Aβ.

97.　(Original)　The use of an anti-Aβ antibody to prepare a medicament for use in a method of any one of claims 76.

98-110 (Canceled)